NEW ORLEANS (EGMN) - Carfilzomib, a novel second-generation proteasome inhibitor, has shown itself to be active in relapsed and refractory patients with previous exposure to bortezomib for multiple myeloma.Importantly, peripheral neuropathy was rare and other toxicities were manageable in reports exploring investigational carfilzomib as monotherapy and in combination with a standard regimen of lenalidomide and dexamethasone (Len/Dex)."This is a drug with significant activity, even in bortezomib-refractory...